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Abstract
Despite great strides that have been made over the past several decades in terms
of diagnosis and treatment, breast cancer remains the most commonly diagnosed cancer
in American women and the second leading cause of cancer-related mortality for women
in the United States. Although the benefits of early detection of breast cancer have been
clearly established, the advantages of screening must also be weighed against a potential
corresponding negative psychological impact of screening procedures. The purpose of
the present study was to further investigate the impact of breast cancer screening on
previously unstudied or understudied aspects of psychological and physiological health,
including sleep quality, negative and positive affect, and biomarkers of immune system
response and to explore between-group differences in these markers based on diagnostic
status over the course of time between surgical consult and diagnosis following breast
biopsy. Results indicated substantially impaired sleep quality as well as elevations in
negative affect across the study sample. Higher levels of a biological marker of
inflammation were shown to be associated with poorer sleep quality. Positive and
negative affect were also associated in the study sample, which is thought to be indicative
of a high level of emotional activation during breast cancer screening and diagnosis.
Counter to study hypotheses, results indicated neither improvements in sleep quality or
affect nor decreased levels of serum cytokines were noted in women who received a
benign diagnosis. Conversely, results for several scales indicated improved sleep quality
for women diagnosed with breast cancer relative to women who received a benign
diagnosis, providing support for the argument that it is the experience of uncertainty that
leads to the acute psychological distress consistently shown in women undergoing breast
cancer screening and breast biopsy.
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During the past several decades, breast cancer has emerged as one of the most
widely researched and most publicly supported areas within the broader field of
oncology. However, despite great strides that have been made in terms of diagnosis and
treatment, breast cancer remains the most commonly diagnosed cancer in American
women and the second leading cause of cancer-related mortality for women in the United
States (Ferrante, Chen, & Kim, 2008). It is estimated that approximately 1 in every 8
American women will be treated for breast cancer at some point during her lifetime and
that roughly 1 in every 30 of these women will die as a result of this disease (American
Cancer Society, 2002). As is true for many cancers, the incidence of breast cancer
increased as women grow older, and despite progress in terms of research into
environmental and behavioral risk factors, most cases of breast cancer will occur in
women that do not present with identified predictors of the disease (Colditz, Willett,
Hunter, Stampfer, Manson, & Hennekens, 1993; Seidman, Stellman, & Mushinski, 1982;
Strax, 1987). As risk factors alone are not sufficient to identify individuals that are likely
to develop breast cancer, early identification and screening efforts have increased over
the past decade. According to the American Cancer Society (2009), in excess of one
million women received a breast diagnostic evaluation (most commonly mammography)
in the United States in 2008, with approximately 180,000 resulting in breast cancer
diagnosis (Montgomery, 2010).
The purpose of breast cancer screening is to allow for detection of the disease or
of disease risk factors to allow for early therapeutic interventions and/or preventative
measures, as research has shown treatments are more effective when the disease is
diagnosed at an early stage (Wardle & Pope, 1992). Since comprehensive breast cancer
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screening was first implemented, research has shown that biannual mammography is the
most effective method for reducing mortality in women 50 years or older (Kerlikowske et
al., 1995). Studies have shown substantial reduction in mortality rates among the general
population of women in this age group following the introduction of biannual
mammography into common practice (Absetz, Aro, & Sutton, 2003; deKoning, 2000).
Two large scale controlled mammography trials conducted in Scandinavia (Tabar,
Fagerbery, Duffy, & Day, 1989) and in North America (Shapiro, 1977) demonstrated
greater than 30% reductions in breast cancer mortality as a result of screening.
The utility of breast cancer screening is only achieved if mammography
examinations are administered frequently to large numbers of women throughout the
general population. Such widespread implementation of mammography screening results
not only in a great number of negative tests but also a considerable occurrence of falsepositive or inconclusive test results that require additional follow-up examination
(Andrykowski et al., 2002). Some studies have suggested that roughly 12 women receive
false-positive diagnosis for every one correctly identified case of breast cancer (Wardle &
Pope, 1992). Medical follow-up for an abnormal mammography commonly involves
either repeat mammography exam or the more invasive breast biopsy. Research suggests
that more than 80% of breast biopsies conducted following abnormal mammography
result in benign diagnosis and exponentially higher numbers of benign diagnoses after
repeat mammogram (Skrabanek, 1985). According to Elmore and colleagues (1998) if
ten screening mammograms were conducted in a woman over 50, there would be up to a
75% chance that one false-positive outcome would result. As breast cancer is less
prevalent in younger women, the percentage of false-positive diagnoses would likely
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increase for women under 40 years of age. As predicted by Lerman and Rimer (1995), if
40% of American women over the age of 40 were to undergo mammography screening,
greater than three million would receive false positive or indeterminate results.
Although the benefits of early detection of breast cancer have been clearly
established, the advantages of screening must also be weighed against a potential
corresponding negative psychological impact that might result from participation in
screening procedures even when a malignancy is not identified (Lerman, Rimer, &
Engstrom, 1991; Wardle & Pope, 1992). Although diagnostic and curative breast cancer
surgeries are conducted out of medical necessity, these procedures have been shown by to
result consistently in significantly heightened distress (e.g. Deane & Degner, 1998; Ganz,
Schag, Lee, Polinsky, & Tan, 1992; Montgomery, Weltz, Seltz, & Boybjerg, 2002).
News of an abnormal mammogram is a stressful event that has the potential to increase
individual vulnerability to psychological and physical illness by activating or intensifying
pre-existing psychological issues (Alderete, Juarbe, Kaplan, Pasick, & Perez-Stable,
2006; Brilman & Ormel, 2001). Potential costs of screening vary from trauma resulting
from the identification of disease in symptom-free individuals to increased psychological
stress and anxiety in healthy individuals that receive a false-positive diagnosis (Wardle &
Pope, 1992). There is also a real monetary cost for screening. For every $100 spent on
breast cancer screening, an estimated $33 will be spent on tests that will lead to a falsepositive result (Humphrey, Helfand, Chan, & Woolf, 2002).
Mammography screening has been shown to result in both short-term distress and
anxiety for women with false positive diagnoses (Aro et al., 2000; Brett et al., 1998) and
long term effects such as perceived increased risk for future diagnosis of breast cancer
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(Aro et al., 2000). The acute psychological distress reported might be due to the prospect
of a grave diagnosis, fear of potential cancer treatment, the procedure of the screening
itself which often involves uncomfortable and invasive testing procedures, as well as a
waiting period before definitive diagnosis is made, and/or anxiety around the experience
of a painful and untimely death (Koller, Kussman, & Lorenz, 1996; Wardle & Pope,
1992). Many studies have been conducted concerning breast cancer screening behavior
as well as the psychological impact of a positive cancer diagnosis, but only a handful of
studies have focused on the effects of cancer screening itself resulting in the notification
of a benign diagnosis. One study by Deane and Denger (1998) found that women who
had received a benign diagnosis after breast biopsy demonstrated continued heightened
anxiety and perceived uncertainty relative to those who received a positive breast cancer
diagnosis even after they were informed of their test results. The experience of breast
biopsy appears to be particularly impactful. Lindfors and colleagues (1998) found that
women who had undergone breast biopsy with benign results reported substantially
greater levels of distress and anxiety than those who had received a benign diagnosis after
repeat mammogram. Another study involving a small group of women that had recently
undergone benign breast biopsy after abnormal mammogram found that 5 of the 30
women described the experience as the worst event that had occurred in their lives up to
that time (Gram, Lund, & Slenker, 1990), and two women involved in a retrospective
study by Weil and Hawker (1997) reportedly committed suicide after receiving notice of
abnormal mammogram results.
Overall, a sound body of research shows that a significant number of women that
receive a false-positive mammography test result will experience some adverse
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psychological impact (Lipkus, Halabi, Stirigo, & Rimer, 2000). Most commonly noted
are increased levels of anxiety, intrusive thoughts around breast cancer, and symptoms of
depression (Pisano, Carp & Gallant, 1998). Elevated levels of anxiety, depression, and
other negative emotions have been found to endure for up to five years after receipt of an
abnormal breast cancer screening result (Lipkus et al., 2000; Pisano et al., 1998).
Evidence has also been found that anticipatory distress occurring in the days or weeks
prior to breast biopsy or lumpectomy is associated with post-surgical side-effects,
including increased chance of infection and psychological symptoms including
depression and anxiety (Montgomery & Bovbjerg, 2004).
One explanation that has recently been put forth for the negative psychological
impact of breast cancer screening, even when no malignancy is identified, involves the
level of uncertainty that characterizes the screening process (Montgomery, 2010).
Uncertainty in terms of illness has been defined as the inability of an individual to discern
the meaning of an illness-related occurrence and an inability to ascertain an accurate
prediction of likely outcomes (Montgomery, 2010). This set of circumstances results in
an infringement on a woman’s belief in herself as healthy and leads her to face the
possibility of her own mortality (Jordens, Little, Paul, & Sayers, 2001). Before receiving
a benign or positive diagnosis for breast cancer, women experience a sometimes extended
period of uncertainty as the await breast biopsy results. Despite advances in rapidity of
diagnosis, Ferrante and colleagues (2008) have noted an average length of time interval
from discovery of an abnormal breast mass to definitive diagnosis ranges from 4-6
weeks. Further supporting uncertainty as an important factor in the distress involved in
breast cancer screening, several studies have reported lower levels of distress when
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communication of results is more rapid, waiting times between tests shorter, and referral
to surgery occurs expeditiously (Barton et al., 2004; Ferrante et al., 2008). The degree of
uncertainty that occurs during the diagnostic process is heightened by the fact that the
initial test, mammography, will confirm that breast cancer is possible but does not
immediately determine whether or not a malignancy is present (Andrykowski et al.,
2002).
The majority of published studies that have explored distress during breast cancer
screening have noted the presence of anxiety and distress as persisting through the
diagnostic phase, only resolving when definitive diagnosis is received. Interestingly,
levels of distress decrease following diagnosis, even when the diagnosis received
indicates malignancy (Deane & Degner, 1998; Fridfinnsdottir, 1997; Shaw, Wilson, &
O’Brien, 1994). Levels of anxiety in women during the period of uncertainty before
diagnosis are equivalent to those noted among patients admitted to in-patient psychiatric
units for treatment of acute anxiety disorders (DeKeyser, Wainstock, Rose, Converse, &
Dooley, 1998; Scott, 1983). Concern around the psychological effects of uncertainty
during breast cancer screening has increased since the introduction of broad screening
programs. The experience of breast cancer screening has been reported as negatively
impacting treatment outcomes in women diagnosed with the disease (Thorne, Harris,
Hislop, & Vestrup, 1999), and also impact behavioral changes in women that receive a
benign diagnosis, including reduced likelihood that these women will comply with future
screening recommendations (Andrykowski et al. 2002; Barton et al., 2004; Brett,
Austoker, & Ong, 1998; Haas, Kaplan, McMillan, & Esserman, 2001; Lampic, Thurfjell,
Bergh, & Sjoden, 2001; Lowe, Balanda, Del Mar, & Hawes, 1999; Olsson, Armelius,
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Nordahl, Lenner, & Westman, 1999). One study, conducted by Schnur and colleagues
(2008), found increased levels of psychological distress in women scheduled for breast
biopsy relative to a group of women scheduled for lumpectomy, which is a much more
invasive procedure that can result in substantial breast tissue loss. The authors believe
that the increased level of uncertainty involved in breast biopsy, where diagnosis and
need for future treatment are unknown, relative to lumpectomy, was responsible for this
unexpected finding (Schnur et al., 2008). In another study also conducted by Schnur and
colleagues (2005) levels of psychological distress in pre-biopsy patients were noted to be
higher than those found in a sample of women following definitive diagnosis of
metastatic breast cancer.
The evidence for the negative impact of breast cancer screening is not uniform
and a number of studies examining the impact of false-positive cancer screening
(abnormal mammogram followed by normal breast biopsy) have shown negative
psychological effects to be neither severe nor persistent (Lerman et al., 1991; Wardle,
Pernet, Collins, & Bourne, 1994). Other researchers have shown that some psychological
characteristics, such as active coping and social support, are positively related to wellbeing in women with false-positive breast cancer screening results, which provides some
indication that buffering effects might be possible (Blutton, Pakenham, & Buckley,
1999).
The majority of the literature concerned with the effects of breast cancer
screening is not only methodologically limited, as these studies often use self-report
measures that are retrospective in nature, but prior research has also been limited in terms
of the psychological and behavioral characteristics that have been assessed. State and
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trait anxiety, depression, and breast-cancer specific worry have been the most common
focal points, with some studies identifying heightened levels of these constructs and some
failing to find differences between women undergoing breast cancer screening and
control samples (Ekeberg et al., 2001). While prior research has examined the impact of
breast cancer screening on specific aspects of mood/affective state, primarily depression
and anxiety, and behavior in terms of coping strategies, none to date have been conducted
that explore a more balanced mood profile, including both positive and negative affect, or
that examine the impact of screening on specific daily behaviors, such as sleep,
commonly effected by stress. In addition, although prior research has shown a clear
profile of immune system changes following breast cancer treatment (Lutgendorf, 2009;
Sepah & Bower, 2009), few studies have explored the potential impact of the breast
cancer screening process on biological markers of immune system functioning. One
possible explanation for the variability of findings evidenced in the literature is that the
measures commonly included in test batteries are not picking up effects specific to the
short-term experience of acute stress that characterizes breast cancer diagnostic
screening.
Although a great deal of support has been shown for the increased prevalence of
depressed mood, anxiety, and chronic stress in patients undergoing treatment for breast
cancer (eg. Gram et al., 1990; Koller, Kussman, & Lorenz, 1996; Pisano et al., 1998), it is
possible that the impact of screening and diagnosis is manifesting across a broader profile
of symptoms. In order to investigate this possibility, the present study seeks to examine
the impact of breast cancer screening and early diagnosis on several constructs known to
impact in patients undergoing treatment for breast cancer that have been widely
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understudied in women undergoing breast cancer screening. These include sleep quality,
mood state in terms of both positive and negative affect, and immune system functioning.
To date, only one published study has investigated immune system (DeKeyser,
Wainstock, Rose, Coinverse, & Dooley, 2004) functioning during breast cancer screening
in women that will go on to receive both benign and positive diagnoses, and a recent
review of the literature has not identified a single published study examining the impact
of breast cancer screening on sleep or negative and positive affect.
Sleep and Affect. At the National Institute of Health State of the Science
conference (NIH, 2004), sleep and mood disturbance were identified as the most
frequently occurring and debilitating symptoms of cancer and cancer treatments. Sleep
quality has been shown to impact reported symptoms of fatigue, pain tolerance and
severity, and immune system functioning; poor sleep has been related to symptoms of
depression and anhedonia (Dickstein & Moldofsky, 1999; Sheev, 1996; Irwin, 2002).
Although the impact of breast cancer screening on sleep quality and quantity has not been
fully explored to date, problematic sleep has been established as a significant issue for
cancer patients and is often the target of pharmacological intervention as a part of
adjuvant cancer treatment (Derogatis, Feldstein, & Morrow, 1979; Goldberg & Mor,
1985). Although figures have varied widely, the overall prevalence of significant sleep
disturbance in cancer patients has been estimated to be as high as 95% (Thomas, 1987).
While the number of studies that have investigated the rates of sleep disturbance in
women suffering from breast cancer is limited, the existing literature notes that these
patients frequently report unsatisfactory sleep and experience sleep problems, including
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frequent awakenings, while undergoing chemotherapy or radiation treatment (Carpenter
& Andrykowski, 1998; Berger, 1995; Berger, 1998; Berger & Farr, 1999; Knobf, 1986)
One study found a high percentage of sleep disturbance in a sample of women
undergoing treatment for breast cancer and also demonstrated that these sleep problems
predicted lower self-reported quality of life (Fortner, Stepanski, Wang, Kasprowicz, &
Durrence, 2002). The authors also noted that while patients that were currently
undergoing treatment for breast cancer (radiation or chemotherapy) showed a trend
toward greater sleep disturbance, that levels of sleep disturbance in these patients was not
higher than in those that were not currently undergoing treatment. This would suggest
that sleep problems in cancer patients are not entirely due to the negative effects of
radiation and chemotherapy treatments. One possible explanation for this finding might
be that the sleep issues reported by cancer patients might be due in part to psychological
factors, such as stress, anxiety, or depression, that have been shown to impact sleep
quality in otherwise physically healthy individuals (Fortner et al., 2002; Lutgendorf &
Costanzo, 2003; Spiegel & Sephton, 2001; Antoni, 2003).
Importantly, several investigators have cited changes in sleep quality as early
symptoms of a broader pattern of systemic dysregulation. Dysregulation of several
interconnected circadian systems has been demonstrated in women with breast cancer,
including the adrenal system, the stress response system, and the autonomic nervous
system, which is responsible in part for sleep regulation (Bovbjerg, 2003; Sephton and
Spiegel, 2003; Touitosu, Bogdan, Levi, Benavides, & Auzeby, 1996). Dysfunction
across these symptoms has also been shown to be associated with a more rapid course of
disease progression in some cases (Bovbjerg, 2003; Sephton and Spiegel, 2003; Touitosu
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et al., 1996). Other factors, such as high levels of stress and psychological disorders such
as depression, may contribute to disruption of normal circadian rhythms and might
therefore indirectly contribute to shorter survival time in breast cancer patients (Antoni,
2003; Carlson, Campbell, Garland, & Grossman, 2007; Lutgendorf & Costanzo, 2003;
Spiegel & Sephton, 2001). Therefore, changes in sleep pattern and/or sleep quality might
provide a useful marker of risk for disruption of normal circadian rhythm and comorbid
psychological symptomology. As sleep quality is also related to psychological factors
such as anxiety and depression, it is possible that sleep disturbance or changes in sleep
quality might be evident in women undergoing breast cancer screening even if symptoms
of depression and anxiety are not detectable.
Mood disturbance has also been noted in non-cancer populations as associated
with multiple physical, immunological, and psychological changes, including increased
reported severity of pain, increased levels of pro-inflammatory cytokines, and increased
symptoms of depression (Bardwell et al., 2006; Lee et al., 2004; Weitzner et al., 1997).
Approximately 20-40% of women with breast cancer experience and report experiencing
mood disturbances at some point during the course of treatment (Badger et al., 2004).
Although several studies have found support for increased symptoms of subjective
distress, most commonly measured via assessment of depression or anxiety, in women
undergoing breast cancer screening, results have been inconsistent (e.g., Ekeberg et al.,
2001).
In order to further explore mood disturbance in women in the diagnostic phase of
breast cancer treatment, the present study will explore the impact of screening and
diagnosis on levels of self-reported positive and negative affect. Positive and negative
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affect are commonly described as independent constructs that represent separate but
related components of mood state (Watson, Clark, & Tellegen, 1999). Positive and
negative affect are representative of dimensional mood states with high negative affect
characterized by the experience of subjective distress and unpleasurable engagement
while positive affect represents subjective feelings of satisfaction and pleasurable
engagement with one’s environment (Watson & Clark, 1984). High levels of positive
affect have been associated with high energy, extraverted behavior, improved
concentration, and emotions such as enthusiasm and alertness, and low levels of positive
affect are related to feelings of sadness, disengagement, and lethargy (Crawford & Henry,
2004). Alternatively, high negative affect is related to neuroticism, anxiety, and the
emotional experience of guilt, anger, fear and nervousness, while low negative affect is
related to feelings of calmness, relaxation, and serenity (Crawford & Henry, 2004). By
including measures of both positive and negative affect in the present study, we hope to
not only discern the presence of negative emotional activation but also to examine the
impact of breast cancer screening on positive emotional activation, an area that has to
date remained unexplored.
Immune System Markers. As was discussed above, individuals suffering from
chronic illnesses, including cancer, often exhibit diverse psychological symptomology
including fatigue, anxiety, and depression (e.g., McDaniel, Musselman, Porter, Reed, &
Nemeroff, 1995). Although the traditional method for assessment of psychological
symptoms has been via self-report questionnaire or interview-based measures, prior
clinical research suggests a strong relationship between disease related inflammation and
depression in patients suffering from chronic illnesses, including diabetes, obesity, and
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coronary heart disease (Frasure-Smith & Lesperance, 2006). Support for this relationship
has led researchers over the past two decades to explore measurement of biological
markers of immune-related inflammation as a non-self-report technique for assessing
level of psychological and physiological distress (Glaser, Robles, & Sheridan, 2003;
Konsman, Parnet, & Dantzer, 2002; Reichenberg, Yirmiya, & Schuld, 2001).
Inflammatory cytokines are one such biological marker.
Cytokines are known to function as signaling molecules that are related to the
regulation of cellular inflammation and are produced by cells that regulate the human
immune response (Thomson & Lotze, 2003). While multiple classification systems for
cytokines have been developed, these molecules are largely divided into two distinct
groups: cytokines that promote inflammation, termed pro-inflammatory cytokines, and
those that reduce inflammation, referred to as anti-inflammatory cytokines (Dinarello,
2000). Pro-inflammatory cytokines are particularly important in terms of their role in
communication of immune activity to the central nervous and neuroendocrine systems
(Reichlin, 1993). For example, when an infection is present somewhere in the body,
immune regulating cells release pro-inflammatory cytokines which act by signaling for
increased pituitary and adrenocortical secretions to combat pathogens (Blalock, 1989).
Unfortunately, pro-inflammatory cytokines are also involved with chronic
inflammation which has been associated with greater morbidity of diseases including
cardiac disease, cancer, and diabetes (Black, 2003). Chronic inflammation has also been
noted as a contributing factor in cancer proliferation and has been associated with
mortality in breast cancer patients (Hagemann et al., 2007; Pierce et al., 2009). More
positive factors such as positive affect and social support have been associated with
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decreased levels of proinflammatory cytokines (Chida & Steptoe, 2008; Rhyff et al.,
2004). Long term exposure to high concentrations of stress hormones instigates an
immune system response that diminishes the immune system’s ability to respond to the
body’s anti-inflammatory actions, resulting in higher levels of pro-inflammatory
cytokines. (Miller, Cohen, & Richey, 2002). Although few studies have assessed levels
of pro-inflammatory cytokines in breast cancer patients, research has shown that positive
affect in breast and prostate cancer patients is related to higher levels of inflammatory
cytokines and Interleukin-6 (IL6), an endogenous cytokine, across multiple measurement
time-points during a 6-week course of external beam radiation therapy (Seraph & Bower,
2009). In contrast, prior research has also indicated that cancer patients who are high in
positive affect before treatment may have a more efficient inflammatory response, as
reflected in higher levels of pro-inflammatory cytokines during treatment (Lutgendorf,
2009).
During the course of an illness, especially one characterized by prolonged
symptoms such as breast cancer, depression and irritability are often reported as well as
mild cognitive issues including impairment of attention, concentration, and short-term
and working memory (Dantzer, O’Connor, Freund, Johnson, & Kelley, 2006). The
symptoms commonly associated with sickness are in fact largely due to the body’s
immune response, which is characterized by changes in the autonomic and endocrine
systems triggered by accessory immune cells and mediated by pro-inflammatory
cytokines (including C-reactive protein and IL-6). C-reactive protein (CRP) is an acute
phase protein that is associated with systematic inflammation in the body (American
Heart Association, 2010). As was previously stated, pro-inflammatory cytokines
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function by coordinating the body’s local and systemic inflammatory response to
pathogens in order to combat infectious agents. However, pro-inflammatory cytokines
can also act on the brain and the periphery to cause sickness symptoms including fatigue
and depression (Dantzer et al., 2006).
In the past decade, researchers have found that the immune response can cause
not only symptoms associated with sickness but can also can result in psychological
symptoms, including anxiety and depression, in physically ill individuals with no history
of mental disorder (Dantzer et al., 2006). For individuals with cancer, a prolonged
immune response to the presence of tumor cells leads to an overabundance of proinflammatory cytokines (Coussens & Werb, 2002). High levels of interleukin-6 (IL-6), a
common circulating pro-inflammatory cytokine, have been associated with more negative
outcomes in patients with breast cancer (Zhang & Anachi, 1999), and IL-6 is thought to
stimulate increased tumor cell growth and to contribute to recurrence and metastasis of
breast cancer (Balkwill & Mantovani, 2001; Leek & Harris, 2002). IL-6 has also been
associated with disease stage progression in breast cancer (Rao, Dyer, Jameel, Drew, &
Greenman, 2006). Pro-inflammatory cytokines have also been associated with symptoms
of depression (Musselman et al., 2001) and fatigue (Bower et al., 2000) in breast cancer
patients. Although elevated levels of proinflammatory cytokines have been related to
increased rate of disease progression in cancer patients, the findings have been somewhat
inconsistent (Lyon, McCain, Walter, & Schubert, 2008). Some studies have found
differences in level of pro-inflammatory cytokines in breast cancer v. controls (Lyon et
al., 2008) and some have not (Pusztai et al., 2004).
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Although multiple studies have explored the involvement of pro-inflammatory
cytokines in breast cancer, to our knowledge only one published study has investigated
markers of immune function in women undergoing breast cancer screening. DeKeyser
and colleagues (2004) looked at distress and immune function in women with suspected
breast cancer. The authors reported associations between psychological distress,
symptom distress, and levels of a serum cytokine, tumor necrosis factor alpha. However,
the authors did not find differences in levels of cytokines between women with a benign
diagnosis and women diagnosed with breast cancer (DeKeyser et al., 2004). In order to
further explore immune system functioning in women undergoing breast biopsy and also
to explore potential associations between immune markers, mood state, and sleep quality,
the present study will involve measurement of two known immune response markers: IL6 and CRP before and after breast biopsy.
Summary. Overall, prior research consistently suggests that the screening and
early diagnostic phase of breast cancer treatment represents an acutely stressful
experience for women. Several studies have noted increased symptoms of distress,
depression and anxiety occurring during this time, with some studies reporting continued
elevations in negative psychological symptoms persisting for months to years following
even a benign diagnosis. One possible explanation for the distress that characterizes the
diagnostic phase for breast cancer is the prolonged period of uncertainty experienced by
women awaiting diagnosis via breast biopsy following abnormal mammogram. Although
a substantial amount of research has explored depression, anxiety, social support and
coping skills in women with suspected breast cancer, none to date have explored the
impact of breast cancer screening on positive and negative affect or sleep quality. In
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addition, only one published study to date has investigated levels of pro-inflammatory
cytokines in women undergoing breast biopsy, and no study to date has explained the
associations of these factors.
The purpose of the present study is to further investigate the impact of breast
cancer screening by exploring changes in sleep, negative and positive affect, and
biomarkers of immune system response, during the time between abnormal
mammography and diagnosis following breast biopsy in a population of women with
suspected breast cancer. As no prior research has involved an examination of sleep
quality or negative and positive affect, the first primary aim of the present study is to
determine if levels of sleep difficulty and affect are elevated in women with suspected
breast cancer relative to normative samples. Then, we will explore potential relationships
among study measures to determine if associations between serum cytokine levels, sleep
quality, and affect are present in women undergoing breast cancer diagnostic testing. We
will also explore any changes that might occur in terms of study variables before and
after breast cancer diagnosis. Finally, the study sample will be split into two subgroups
based upon diagnosis and potential between-group differences in sleep quality, affect,
and immune markers will be examined.
Based upon prior research that has consistently reported increased psychological
distress among women with suspected breast cancer, we expect that our study sample will
demonstrate decreased sleep quality, decreased positive affect, and increased negative
affect relative to normative PSQI and PANAS scale scores. We also expect that these
elevations will decrease post-biopsy for the benign diagnosis group but will remain stable
for those diagnosed with breast cancer. Elevations in serum cytokine levels are also
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expected to increase during the pre- to post-biopsy period for both groups due to the
stressful nature of the experience of breast cancer diagnostic testing. Finally, we expect
to find associations between sleep quality, affect, and immune markers for both the
benign diagnosis and positive breast cancer diagnosis groups.
Method
Participants and Procedure. Participants for this study were a convenience
sample taken from a group of 100 consecutive patients who have been referred to the
surgeons of the Neag Comprehensive Cancer Center for evaluation. The study sample
consisted of women from 20-80 years of age who have been referred for follow up
evaluation after an abnormal breast exam or mammogram. Participants were approached
by study staff during their initial surgical consult and asked to complete two short series
of questionnaires and to provide blood samples for biological analyses. Pre-biopsy
questionnaires were completed following initial surgical consult for breast biopsy. Postbiopsy questionnaires were completed after participants obtained results of their breast
biopsy. Participants had the option to complete questionnaires either in the consult office
within the cancer center or via a web-based survey from home if preferred. Biopsy
results were retrospectively determined at the time of data consolidation from
participants’ pathology reports and charts.
Measures
Pittsburgh Sleep Quality Index (PSQI). The Pittsburgh Sleep Quality Index
(PSQI; Buysse, Reynolds, Monk, Berman, & Kupfer, 1989) is a standardized self-report
measure of sleep quality designed to determine patterns of sleep dysfunction through
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assessment of both qualitative and quantitative data and also to allow for calculation of a
single global score to convey quality and severity of overall sleep problems (Carpenter &
Andrykowski, 1998). A global PSQI score above 5 is considered as an indication of
significant sleep disturbance (Buysse, Reynolds, Monk, Berman, & Kupfer, 2000). The
PSQI consists of 19 items that, taken together, produce a single global sleep quality index
as well as seven component scores aimed at representing standard areas most commonly
assessed by clinicians. These component scores reflect sleep quality, sleep latency, sleep
duration, sleep efficiency, sleep disturbance, use of sleep medications, and daytime
dysfunction. The PSQI also collects information about typical bed time, wake time,
number of actual hours slept, and number of minutes to fall asleep. The other fifteen
PSQI items are forced-choice Likert-type scales. Higher scores on the global index as
well as the seven component scales represent poorer sleep quality. The psychometric
properties of the PSQI were originally supported with data collected from a sample of 52
healthy subjects and 96 individuals with a history of sleep problems (Buysse et al., 1989).
Since that time, the PSQI has been utilized in a variety of populations, including healthy
individuals of varying ages (Hoch, Dew, Reynolds, & Monk, 1994), trauma survivors
(Mellman, Kulick-Bell, Hebding, & Nolan, 1995), and patients with mood disorders,
panic disorders, social phobia, and breast cancer patients (Nierenberg, Adler, Peselow,
Zornberg, & Rosenthal, 1994; Pasternak, Reynolds, & Houck, 1994; Reynolds, Hoch, &
Buysse, 1993; Stein, Chartier, & Walker, 1993). The PSQI has demonstrated internal
consistency, convergent and discriminant construct validity, and consistent Chronbach’s
alphas across multiple samples (Carpenter & Andrykowski, 1998).
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Positive and Negative Affect Schedules (PANAS). The Positive and Negative
Affect Schedule (PANAS; Watson et al.,1988) is a 20-item self-report measure that
consists of two 10-item mood scales which represent positive and negative affect
respectively. The PANAS was developed using a sample of undergraduate students but
has since been validated with a wide variety of adult populations. Each of the 20 items is
rated on a 5-point forced-choice Likert-type scale ranging from 1 (very slightly or not at
all) to 5 (extremely) the indicate the degree to which the participant endorses a particular
feeling state within a specified time frame. Scores for each affect scale range from 1050, with higher scores representing higher levels of negative or positive affect. Results of
a recent study with a large, non-clinical sample of 1,003 members of the general adult
population provided normative data for both positive (mean = 31.31, SD = 7.65) and
negative (mean = 16, SD = 5.9) affect scales (Crawford & Henry, 2004). Time frame for
the PANAS can be adjusted to reflect positive and negative affect for any range from in
the present moment to over the course of the last year. Watson, Clark, and Lee (1998)
have demonstrated alpha coefficients for various time reference periods ranging from .84
to .90. Both subscales of the PANAS have also been shown to demonstrate discriminant
and convergent validity with other established measures. The two scales have been
shown to be highly internally consistent and stable (Watson, 1988).
Interleukin-6 (IL-6) and C-Reactive Protein (CRP). Blood samples were
collected from participants via inner elbow venipuncture and collected into vacutainer
tubes. Samples were prepared via centerfuge and serum was collected and subsequently
frozen at negative eighty degrees celcius. Serum was then analyzed for levels of IL-6 and
CRP using Luminex Multiplex Bead assays according to manufacturer’s instructions.
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Data Analyses. To ensure a normal distribution of scores, values above or below
three standard deviations of the mean for CRP and IL-6 were removed for further
analyses. Square root and natural log transformations were then conducted for CRP and
IL-6, respectively. Non-detectable levels of IL-6 were designated as zero values for
subsequent analyses.
All data analyses were performed using SPSS version 17.0 (SPSS, Inc., 2009).
We first conducted exploratory data analyses to assess demographic composition of the
sample. Bivariate correlation matrices were then computed in order to determine
associations between self-report measures (PSQI and PANAS) and biological markers
(CRP and IL-6), and between these variables and potential covariates. Potential
covariates included age of participants, time interval between pre- and post-biopsy time
points, as well as several self-report questionnaire measures. Self-report measures
included the Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1982),
which detects states of depression and anxiety in medical patients; the European
Organization for Research and Treatment of Cancer quality of life questionnaire
(EORTC; Aaronson et al., 1993), which assesses quality of life in cancer patients; and the
Brief Fatigue Inventory (BFI; Mendoza et al., 1999), which assesses fatigue in clinical
settings. The data were then spit into subgroups based on cancer diagnosis and
correlational analyses were repeated. Partial correlation matrices were then computed in
order to allow for determination of associations between all study measures with
covariates included. General linear model repeated measures tests were conducted to
examine change in study measures over time with cancer diagnosis as a between subjects
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variable. Finally, residualized change scores were computed to further examine
relationships between study measures over time.
Results
Participant Characteristics. Relevant demographic information for the total
study sample as a whole and sub-grouped by diagnostic status is detailed in Table I.
Although complete questionnaire and biological data were obtained for a total of 47
participants, limited demographic data were available. The average age of participants
was 53-years-old (SD = 10.67). The interval of time between completion of the two sets
of study questionnaires varied with a mean time to completion of 25.5 days (SD = 26).
The study sample was comprised predominantly of Caucasian women (51.1%) with small
numbers of African-American (4.3%) and Hispanic (6.4%) also included. Information
regarding ethnicity was not available for 18 of 47 participants. All participants
underwent surgical breast biopsy over the course of their participation in the present
study, with 32 (68.1%) women receiving a benign diagnosis and 15 (31.9%) diagnosed
with breast cancer.
Descriptive Statistics for Study Measures. Descriptive characteristics for all study
scales and biological markers are detailed in Tables IIa and IIb. The average detected
serum concentration of CRP at the pre-biopsy time point was 7,248.06 mg/dL (SD =
7,823.91) and at post-biopsy was 8,358.26 mg/dL (SD = 8,597.71). Mean detected IL-6
at the pre-biopsy time point was 252.168 pg/mL (SD = 545.15) and at post-biopsy was
245.86 pg/mL (SD = 518.55). At the pre-biopsy time point, average score on the PANAS
positive affect (PA) subscale was 25.1 (SD = 6.1), which is within normal range for this
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scale. Post-biopsy average negative affect (NA) score was 29.79 (SD = 6.34). This score
is more than two standard deviations above the mean score for normative samples. At the
post-biopsy time point, average PA was 23.75 (SD = 6.51), which is within normal range.
Post-biopsy average NA score was 29.32 (SD = 7.44), which is also more than two
standard deviations above the normative mean score. Average global PSQI index score
at pre-biopsy was 7.27 (SD = 3.31) and post-biopsy average score was 7.02 (SD = 3.59).
The majority of participants demonstrated significant sleep disturbance (average score
above 5) at both the pre- and post- biopsy time points, regardless of cancer status.
Associations between PSQI, PANAS and Biological Markers. Correlation
coefficients were calculated to explore potential associations between study measures and
potential covariates. Partial correlation coefficients were then calculated to explore these
associations while statistically controlling for anxiety (HADSA), depression (HADSD),
well-being (EORTC), and fatigue (BFI) at baseline. Results are detailed in Table III.
Transformed CRP at both pre- and post-biopsy time points was positively
associated with post-biopsy PSQI scores (r = .384, p<.05; r = .375, p<.05). Transformed
IL-6 was not associated with any other study measure. Both positive and negative affect
at the pre-biopsy time point were associated with positive (r = .798, p<.01) and negative
(r = .917, p<.01) affect post-biopsy. The PANAS positive affect subscale was also
shown to be positively associated with the negative affect subscale at both pre-biopsy (r =
.492, p<.05) and post-biopsy (r = .459, p<.05) time points.
Data were then split into two subgroups based upon diagnostic status and partial
correlation coefficients were once again computed. For participants with a benign breast
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cancer diagnosis, post-biopsy transformed CRP was associated with post-biopsy PSQI (r
= .482, p = .05) but not with pre-biopsy PSQI, although that relationship did approach
significance (r = .429, p = .086). For participants with a positive diagnosis of breast
cancer, pre-biopsy transformed CRP was associated with pre-biopsy negative affect (r =
.758, p<.05). No associations between IL-6 and other measures were found for either
group. No associations were found between PSQI and other measures. Pre-biopsy
positive affect for participants with a benign diagnosis was shown to be related to postbiopsy positive affect (r = .795, p<.01) and to post-biopsy negative affect (r = .851,
p<.01) and time two (r = .753, p<.01). Pre-biopsy negative affect for these participants
was associated with post-biopsy negative affect (r = .680, p<.01) and to post-biopsy
positive affect (r = .769, p<.01). For participants with a positive cancer diagnosis, prebiopsy positive affect was associated with pre-biopsy negative affect (r = .824, p<.05) but
not with positive or negative affect post-biopsy. Pre-biopsy negative affect for this group
was associated with post-biopsy negative affect (r = .459, p<.05) and post-biopsy positive
affect was associated with post-biopsy negative affect (r = .898, p<.05).
PSQI Component Scales. General linear model repeated measures analyses were
conducted to explore potential main effects (cancer status and time point) as well as
interaction effects (cancer status x time point) for PSQI component scales. For all PSQI
component scales, a higher score indicates increased impairment. For all analyses, time
interval between pre- and post-biopsy time points was entered as a covariate. Results are
depicted in Figures 1-3. For the PSQI component score reflecting sleep latency, a
significant interaction effect was found between time point and cancer status (F(1, 33) =
4.725, p<.05), indicating a pre- to post-biopsy improvement in sleep latency scores for
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participants diagnosed with breast cancer relative to those with a benign diagnosis. No
significant main effects were demonstrated for diagnostic status or for time point. A
similar result was shown for the PSQI component score representing daytime
dysfunction, with a significant interaction effect between time point and cancer status
(F(1, 33) = 7.008, p<.05), indicating a pre- to post-biopsy improvement in daytime
dysfunction scores for participants diagnosed with breast cancer relative to those with a
benign diagnosis. No significant main effects were found for cancer diagnostic status or
for time point.
Group Differences in Immune Response Markers and Affect. General linear
model repeated measures analyses were also conducted to explore potential main effects
(cancer status and time point) as well as interaction effects (cancer status x time point) for
PSQI global scores, PANAS positive and negative affect scales, CRP and IL-6. No
significant main effects or interaction effects were found for PSQI, PANAS positive and
negative affect scales, or IL-6. However, a significant main effect was found for CRP
(F(1, 41) = 4.241, p<.05), indicating an increase in transformed CRP from pre- to postbiopsy regardless of cancer diagnosis (see Figure 4). No significant main effect for
cancer status or significant interaction between cancer status and time point was found.
Results are detailed in Figure 4.
In order to further examine relationships between study scales and immune
markers, residualized change scores were computed for PANAS positive and negative
affect scales, PSQI global scores, transformed CRP and transformed IL-6. Delta scores
for each of these variables were created and entered into stepwise linear regression
analyses. Post-biopsy values served as dependant variables. Covariates were entered as

26

level-one independent variables, pre-biopsy values were entered as level-two independent
variables, and delta scores were entered as level-three independent variables. Following
initial analyses, data were split into subgroups by diagnostic status and residualized
change scores were calculated once again.
Initial analyses conduced with the total sample did not indicate that any of the
independent variables accounted for a significant change in level of CRP over time.
However, when the data were split by cancer diagnosis, results indicated that for women
who received a benign diagnosis, scores on the PANAS positive affect scale increased
with levels of CRP (F(1,18) = 7.728, p <.05, β = .279). A trend toward significant was
also noted for change in PANAS negative affect scores occurring with increased level of
serum CRP in the benign group (F(1,18) = 3.022, p = .99, β = .194). A similar finding
was also noted when PANAS positive affect score was entered as the dependent variable
for the total study sample, with increased positive affect increasing as serum CRP
increased (F(1,41) = 8.168, p <.01, β = .276). A significant relationship was also
indicated between increases in positive and negative affect over time for the total sample
(F(1,43) = 9.125, p <.01, β = .299). When data were broken into subgroups by diagnostic
status, no significant relationships were noted between positive affect and other variables
for women diagnosed with breast cancer. For the benign group, however, the relationship
between positive and negative affect persisted (F(1,20) = 6.489, p <.05, β = .260). When
PANAS negative affect score was entered as the dependent variable for the total sample,
a significant relationship between positive and negative affect was indicated once again
(F(1,40) = 6.245, p <.05, β = .247). No significant residualized change scores were noted
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for negative affect when data were split by diagnosis. No significant residualized change
scores were noted when IL-6 or PSQI index score were entered as a dependent variables.
Discussion
The overarching purpose of the present study was to further investigate the impact
of breast cancer screening on previously unstudied or understudied aspects of
psychological and physiological health, including sleep quality, negative and positive
affect, and biomarkers of immune system response. This study further aimed to explore
between-group differences in serum cytokine levels, sleep quality, and affect based on
diagnostic status over the course of time between surgical consult and diagnosis
following breast biopsy in order to determine whether receipt of a benign diagnosis will
significantly reduce level of psychological distress. To this end, measurement of sleep
quality, positive and negative affect, and serum cytokines was conducted at two time
points, pre- and post- surgical breast biopsy, in a convenience sample of women referred
to the Neag Comprehensive Cancer center for evaluation of an abnormal breast mass.
A total of 47 participants completed questionnaire and biological measures at both
study time points. Although limited demographic information was available for this
sample, participants were primarily women of a typical age for breast cancer screening
with an average age of 53-years-old, and were primarily Caucasian. All women
underwent a surgical breast biopsy procedure over the course of the study. Of the 47
participants that completed the study, 32 received a benign diagnosis and 15 were
diagnosed with breast cancer. These figures are also consistent with percentages reported
in large scale studies (deKoning, 2000; Wardle & Pope, 1992).

28

As the measures included in the present study had not previously been assessed in
a similar patient population, we first calculated basic descriptive statistics for the group as
a whole, and then by diagnostic subgroup, in order to compare average scores on the
PSQI and PANAS scales for our sample with normative data available for these
measures. As past research consistently reports elevated levels of psychological distress,
we expected that scores on both scales would be significantly elevated relative to
normative data (Crawford & Henry, 2004; Watson et al., 1998). Results confirmed our
hypotheses. For the sample as a whole as well as for diagnostic sub-groups, mean PSQI
global index scores were above the level established by creators of the measure as
indicative of significant sleep disturbance (global score >5). This was true at both preand post-biopsy time points. We next examined the PANAS subscales reflecting
negative and positive affect. As no cut-off scores have been established for this measure,
we used as a comparison sample data from a large (1,003) general population sample of
adult men and women (Crawford & Henry, 2004). Results indicated that while positive
affect for the total sample and sample subgroups was within normal range at both pre-and
post-biopsy time points. Results for the negative affect scale, however, revealed
substantial elevations in negative affect (greater than two standard deviations above the
normative sample mean) for the total sample and subgroups at both time points. These
results not only provide additional evidence of the stressful nature of breast cancer
diagnostic testing but also provide an initial indication that sleep and mood state are
negatively impacted during the breast cancer diagnostic phase.
Another aim of this study was to examine associations between sleep quality,
negative and positive affect, and serum cytokine levels. To serve this purpose, partial
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correlation analyses were conducted to evaluate relationships between these study
variables. In order to control for potentially confounding factors, anxiety, depression,
well-being, and fatigue were statistically controlled for these analyses. As sleep quality,
negative and positive affect, and levels of serum cytokines have been shown to be
impacted during stressful experiences (e.g. Gram et al., 1990; Pisano, Earp, Schell,
Vokaty, & Denham, 1998; Wardle & Pope, 1992), we expected that relationships would
emerge between these study variables for our sample. Our hypotheses were partially
confirmed by analyses conducted with the total sample. Results indicated that higher
levels of serum CRP at both time points were associated with poorer sleep quality at the
post-biopsy time points. This finding indicates that women who were experiencing and
reporting lower quality of sleep post-biopsy also demonstrated increased levels of this
circulating pro-inflammatory cytokine, a biological marker of stress-related immune
system activation. However, no such associations were found between IL-6 and the other
study scales. Although this finding does not support our hypotheses, it is likely that our
failure to detect relationships between IL-6 and the other study scales is due at least in
part to the high number of participants with non-detectable levels of IL-6. In order to
include these participants’ data for analyses, non-detectable levels were entered as zero,
which resulted in a negatively skewed distribution, potentially inhibiting our ability to
statistically detect associations. As other studies have shown that decreases in IL-6 are
associated with the distress experienced by patients undergoing cancer screening (Glaser
et al., 2003; Konsman et al., 2002; Reichenberg et al., 2001), it is likely that we would
have seen similar results if the variability of our data were not limited.
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An additional unexpected finding also emerged from correlational analyses.
Results indicated a positive association between positive and negative affect for the total
sample at both pre- and post-biopsy time points, suggesting that participants with higher
levels of positive affect also demonstrated higher levels of negative affect. This is
somewhat unusual as prior literature consistently reports negative correlations between
these two scales (Watson, 1998). Although positive and negative affect are now widely
considered to reflect distinct constructs, elevated levels of both positive and negative
affect are not typically noted in prior research. However, as was previously discussed,
the diagnostic phase of breast cancer treatment represents a highly stressful experience
that is characterized by anxiety and psychological distress. As high levels of both
positive and negative affect represent emotional activation (Watson et al., 1988), it is
fitting that elevations across these scales would be exhibited by women undergoing a
highly emotionally activating experience. As lower levels of positive affect are typically
associated with symptoms of depression (Crawford & Henry, 2004), these results are
consistent with prior research that has not found a substantial increase in depression for
women undergoing breast biopsy relative to healthy samples (Ekeberg et al., 2001).
Following these group-wide analyses, the sample was divided into subgroups
based on cancer diagnosis and analysis of associations between study measures was
repeated. Results for the benign group once again indicated an association between
serum CRP and sleep quality, with higher CRP related to poorer post-biopsy sleep quality
for this group. This relationship was not detected in the breast cancer group. However, it
is unclear whether this is truly reflective of a lack of association or to a lack of statistical
power due to the limited number of participants in this subgroup. Despite the small
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number of participants in the positive diagnosis group, negative affect for this group was
related to level of serum CRP, indicating that participants with higher pre-biopsy
negative affect also demonstrated higher levels of pre-biopsy serum CRP. This finding is
in keeping with study hypotheses that predicted associations between study measures
indicating psychological distress and serum cytokine levels. The group-wide relationship
between positive and negative affect was also demonstrated by sub-group analyses. For
both the benign and positive diagnosis subgroups, participants with higher levels of
negative affect also demonstrated higher levels of positive affect at both pre-and postbiopsy time points. If the association between high positive and negative affect is
reflective of a broad emotional activation resulting from an acutely stressful experience,
than these results might be taken as support for the assumption that breast cancer
screening is associated with acute emotional activation even for women who receive a
benign diagnosis.
To further examine the relationship between changes in PSQI, PANAS scales,
and cytokine levels over time, residualized change score analyses were conducted.
Results of these analyses further supported the presence of high levels of both positive
and negative affect across diagnostic subgroups. Not only was increased positive affect
predictive of increases in serum CRP for women who received a benign diagnosis, but
increases in positive affect were predictive of increases in negative affect both for the
group as a whole and within each diagnostic subgroup.
Another aim of the present study was to determine whether participants would
demonstrate a differential pattern of impairment in terms of sleep quality, affect, and
serum cytokine levels depending on their diagnostic status. As a positive breast cancer
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diagnosis is sometimes a traumatic experience, we expected that impairments in the
positive diagnosis subgroup would remain stable or increase from pre- to post-biopsy
while scores for the benign group would indicate improvement in terms of sleep and
affect, along with a corresponding decrease in serum cytokines, after biopsy results were
received. These hypotheses were not confirmed. Results indicated neither improvements
in sleep quality or affect nor decreased levels of serum cytokines were noted in women
who received a benign diagnosis. Conversely, results for several scales indicated
improved sleep quality for women diagnosed with breast cancer relative to women who
received a benign diagnosis. Results of repeated measures analysis that compared PSQI
component scores for benign and positive diagnosis subgroups across time points
indicated that women with a positive diagnosis demonstrated improved levels of sleep
latency and daytime dysfunction relative to those with a benign diagnosis from pre- to
post-biopsy. In other words, women who were diagnosed with breast cancer showed
improvements in the time it took to fall asleep and felt more rested after receiving their
diagnosis relative to women who received a benign diagnosis.
Although these results were contrary to our hypotheses, they do provide further
support for the argument that it is the experience of uncertainty that leads to the acute
psychological distress consistently shown in women undergoing breast cancer screening
and breast biopsy. As was previously noted, uncertainty in illness occurs when an
individual is made aware of the possibility that they might have a life-threatening disease
without being able to immediately confirm positive or negative diagnosis (Jordens, Little,
Paul, & Sayers, 2001). Exposure to the period of uncertainty between detection of an
abnormal breast mass and definitive breast cancer diagnosis has been shown to impact
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both the beliefs and the behaviors of women who receive a benign diagnosis. Studies
have shown that women who have received a benign diagnosis following breast biopsy
are less likely to comply with future recommended screening procedures (e.g.
Andrykowski et al., 2002; Barton et al., 2004). Increase breast cancer specific worry has
also been shown in women who have received a benign breast biopsy as has heightened
perceived 10-year and lifetime risks for eventual positive breast cancer diagnosis
(Andrykowski et al., 2002). Overall, evidence suggests that it is the experience of
uncertainty that is causing the acute distress experienced by women undergoing breast
biopsy. If this is the case, then it is possible that receipt of a benign diagnosis serves to
perpetuate feelings of uncertainty as women who receive such a diagnosis believe that
they are at an increase risk for developing breast cancer in the future. While receipt of a
positive diagnosis is a frightening and traumatic experience, it also represents a resolution
of uncertainty. Under these circumstances, the results of the present study might indicate
that women with a benign diagnosis fail to demonstrate improvements in sleep quality
and affect because they continue to experience uncertainty around their long-term
physical health.
Results also indicated that both groups showed an increase in serum CRP from
pre-to post biopsy time points regardless of the diagnosis that they received. This finding
provides further support for the impact of the acute stress experienced during breast
cancer diagnostic testing on levels of this circulating pro-inflammatory cytokine. No
additional findings emerged in terms of levels of serum IL-6 or in terms of negative and
positive affect scales.
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Limitations and Future Directions. Several limitations were apparent in the
present study. The primary limitation of this study was the size and diversity of the study
sample, which primarily consisted of Caucasian women 50 years or older. We were also
limited in terms of demographic information regarding socioeconomic status, medical
history, and family history of breast cancer diagnosis. Due to the small number of
participants overall and especially within the positive diagnosis group, it is possible that
analyses were impacted by Type II error. However, the measures included in the present
study are novel and the results that were evidenced provide important direction for future
research.
In order to continue to examine the role of uncertainty in the psychological
distress demonstrated during breast cancer screening and diagnosis, future research
should involve long-term research with larger and more diverse samples that would
specifically examine this construct to determine how uncertainty impacts symptoms of
psychological distress over time for women with benign breast biopsy. If future research
bears out the theory that uncertainty, along with associated psychological distress,
persists beyond receipt of definitive diagnosis for women with benign breast biopsy, than
this might be a fertile area for potential intervention.
Summary. Overall, results of the present study provide additional evidence for the
negative psychological and physiological impact of breast cancer screening and
diagnosis. As sleep quality and positive and negative affect had not previously been
examined within this population, the present study represents the first exploration of the
impact of breast cancer screening on these important constructs. Results indicated
substantial elevations in terms of poor sleep quality and negative affect in this group
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relative to normative samples as well as improved sleep latency and daytime dysfunction
in the positive versus benign diagnosis group. In keeping with prior research, results
indicated increased levels of a biomarker of inflammation from pre-to post-biopsy time
points. Results also indicated a positive association between positive and negative affect
for this sample, and positive and negative affect were shown to be predictive of each
other from pre- to post-biopsy time points both for the group as a whole and for
diagnostic subgroups. These findings might provide initial support for the presence of
broadly heightened emotionality occurring in women undergoing breast cancer diagnostic
testing and might also provide an explanation for inconsistencies in prior research around
the presence of depression symptoms in this population. Finally, results of the present
study provide some additional support for the importance of uncertainty in producing the
acute psychological distress consistently reported in women undergoing breast cancer
screening and breast biopsy.
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Appendices
TABLE I
Demographic Information – Means and Frequencies
Total

Positive
Diagnosis

Benign
Diagnosis

Age Mean Scores (SD)

52.93(10.67)

56.6(8.93)

51.22(11.11)

Time 1 – Time 2 Interval
mean scores (SD)

25.5(26)

17.3(9.91)

29.58(30.61)

4.3%
6.4%
51.1%
38.3%

0%
6.7%
53.3%
40%

6.3%
6.3%
50%
37.5%

Ethnicity
Black, Non-Hispanic
Hispanic
White, Non-Hispanic
Not Reported
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TABLE IIa
Descriptive Statistics, Mean Scores (SD) – Pre-biopsy
Total

Positive Diagnosis

Benign
Diagnosis

PSQI Index Score

7.28(3.5)

7.27(2.71)

7.28(3.86)

PANAS Positive Affect

25.11(6.1)

25.2(5.11)

23.81(6.07)

PANAS Negative Affect

29.79(6.34)

30.1(5.65)

29.66(6.72)

CRP

5612.32(4690.1)

4611.43(3918.59)

6079.4(5002.35)

IL-6

133.7(248.87)

109.8(234.16)

144.82(258.55)

TABLE IIb
Descriptive Statistics, Mean Scores (SD) – Post-biopsy
Total

Positive Diagnosis

Benign
Diagnosis

PSQI Index Score

7.02(3.59)

6.86(3.84)

7.09(3.54)

PANAS Positive Affect

23.74(6.51)

23.6(7.59)

29.81(6.07)

PANAS Negative Affect

29.32(7.44)

27.53(9.0)

30.16 (6.58)

CRP

7048.24(5852.36)

7238.64(6561.77)

6962.2(5617.03)

IL-6

130.69(238.04)

103.85(230.59)

143.22(244.28)
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Table III
Partial Correlations for PSQI, PANAS, CRP and IL-6

PSQI T1

PSQI T2

Panas
Pos T1

Panas
Pos T2

Panas
Neg T1

Panas
Neg T2

Total T1
Total T2
Benign T1
Benign T2
Positive T1
Positive T2

.551*
.516*
.566*

.551*
.516*
.566*
-

.078
.032
.075
-.106
-.204
-.395

-.105
-.222
.193
.145
-.105
-.222

-.008
.186
-.05
.057
-.008
.186

-.225
-.168
.028
.087
-.225
-.168

PANAS Pos
Total T1
Total T2
Benign T1
Benign T2
Positive T1
Positive T2

.078
-.105
.075
.193
-.204
-.376

.032
-.222
-.106
.145
-.395
-.422

.492*
.795*
.647

.492
.795*
.492*
-

.798*
.399*
.851*
.769*
.798*
.399*

.466*
.917*
.753*
.917*
.466*
.917*

PANAS Neg
Total T1
Total T2
Benign T1
Benign T2
Positive T1
Positive T2

-.008
-.225
-.05
.028
.132
-.352

.186
-.168
.057
.087
.103
-.107

.798*
.466*
.851*
.753*
.824*
.712†

.399*
.917*
.769*
.917*
.798*
.466*

.459*
.680*
.459*

.459*
.680*
.459*
-

Total T1
Total T2
Benign T1
Benign T2
Positive T1
Positive T2

.338†
.271
.372
.429†
.419
.008

.384*
.375*
.407
.482*
.687†
.567

.049
-.138
-.083
-.191
.049
-.138

-.060
-.160
.123
.137
.049
-.138

.225
.043
-.058
-.104
.225
.043

-.079
-.146
-.028
.044
-.079
-.146

Total T1
Total T2
Benign T1
Benign T2
Positive T1
Positive T2

.256
.258
.405
.393
.419
.987

.128
.063
.270
.254
.397
.624

.128
.063
.219
.193
.128
.063

.233
.195
.219
.193
.128
.063

.027
-.021
.024
.013
.027
-.021

.253
.214
.197
.195
.253
.214

Scale
PSQI

CRP

IL-6

* p >.05 † p< .10
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80
78

Estimated Marginal Means

76
74
72
Breast Cancer

70

Benign Biopsy

68
66
64
62
60
Pre-Biopsy

Post-Biopsy

Figure A. Pre- to Post-biopsy changes in CRP by diagnostic subgroup.

1.7

Estimated Marginal Means

1.5

1.3

Breast Cancer

1.1

Benign Biopsy
0.9

0.7

0.5
Pre-Biopsy

Post-Biopsy

Figure B. Pre- to post-biopsy changes in Pittsburgh Sleep Quality Index Sleep Latency component scores
by diagnostic subgroup.
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1
0.9

Estimated Marginal Means

0.8
0.7
0.6
Breast Cancer

0.5

Benign Biopsy

0.4
0.3
0.2
0.1
0
Pre-Biopsy

Post-Biopsy

Figure B. Pre- to post-biopsy changes in Pittsburgh Sleep Quality Index Daytime Dysfunction component
scores by diagnostic subgroup.
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Appendix: European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC) *
* The EORTC QLQ-C30 is a copyrighted instrument. It is currently available in the
following languages: Danish, Dutch, French, German, Italian, Japanese, Norwegian, and
Swedish. Requests for permission to use the instrument and for scoring instructions
should be sent either to Neil K. Aaronson, Ph.D., The Netherlands Cancer Institute,
Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands, or to Ann Cull, Ph.D.,
Secretary, EORTC Study Group on Quality of Life, Department of Clinical Psychology,
Outpatient Clinic E, Western General Hospital, Crewe Road, Edinburgh EH4 2XU,
United Kingdom.
We are interested in some things about you and your health. Please answer all of the
questions yourself by circling the number that best applies to you. There are no "right" or
"wrong" answers. The information that you provide will remain strictly confidential.
Please fill in your initials:
Your birthdate (Day, Month, Year):
Today's date (Day, Month, Year):
No

Yes

1. Do you have any trouble doing strenuous
activities, like carrying a heavy shopping bag or
a suitcase?

1

2

2. Do you have any trouble taking a long
walk?

1

2

3. Do you have any trouble taking a short walk
outside of the house?

1

2

4. Do you have to stay in a bed or a chair for
most of the day?

1

2

5. Do you need help with eating, dressing,
washing yourself or using the toilet?

1

2

6. Are you limited in any way in doing either
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your work or doing household jobs?

1

2

7. Are you completely unable to work at a job
or
to do household jobs?

1

2

DURING THE PAST WEEK:
Not
at
A
Quite
All
Little
a Bit

Very
Much

8. Were you
short of
breath?

1

2

3

4

9. Have you
had pain?

1

2

3

4

10. Did you
need to rest?

1

2

3

4

11. Have you
had trouble
sleeping?

1

2

3

4

12. Have you
felt weak?

1

2

3

4

13. Have you
lacked
appetite?

1

2

3

4

14. Have you
felt
nauseated?

1

2

3

4

15. Have you
vomited?

1

2

3

4

16. Have you
been
constipated?

1

2

3

4
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17. Have you
had
diarrhea?

1

2

3

4

18. Were you
tired?

1

2

3

4

19. Did pain
interfere with
your daily
activities?

1

2

3

4

20. Have you
had difficulty in
concentrating
on things,
like reading
a newspaper
or watching
television?

1

2

3

4

21. Did you
feel tense?

1

2

3

4

22. Did you
worry?

1

2

3

4

23. Did you
feel irritable?

1

2

3

4

24. Did you
feel
depressed?

1

2

3

4

25. Have you
had
difficulty
remembering
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things?

1

2

3

4

26. Has your
physical
condition or
medical
treatment
interfered
with your
family life?

1

2

3

4

27. Has your
physical condition or
medical
treatment
interfered
with your
social
activities?

1

2

3

4

28. Has your
physical condition or
medical
treatment
caused you
financial
difficulties?

1

2

3

4

FOR THE FOLLOWING QUESTIONS PLEASE CIRCLE THE NUMBER BETWEEN
1 AND 7 THAT BEST APPLIES TO YOU
29. How would you rate your overall physical condition during the past week?
1
Very
poor

2

3

4

5

6

7
Excellent

30. How would you rate your overall quality of life during the past week?
1

2

3

4

5

6

7
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Very
poor

Excellent

Appendix: Hospital Anxiety and Depression Scale (HADS)

Hospital Anxiety and Depression Scale (HADS)
Patients are asked to choose one response from the four given for each
interview. They should give an immediate response and be dissuaded
from thinking too long about their answers. The questions relating to
anxiety are marked "A", and to depression "D". The score for each answer
is given in the right column. Instruct the patient to answer how it currently
describes their feelings.

A

D

I feel tense or
'wound up':
Most of the time

3

A lot of the time

2

From time to time,
occasionally

1

Not at all

0

I still enjoy the
things I used to
enjoy:
Definitely as much

0

Not quite so much

1

Only a little

2
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Hardly at all

A

D

3

I get a sort of
frightened feeling
as if something
awful is about to
happen:
Very definitely and
quite badly

3

Yes, but not too
badly

2

A little, but it
doesn't worry me

1

Not at all

0

I can laugh and see
the funny side of
things:
As much as I always
could

0

Not quite so much
now

1

Definitely not so
much now

2

Not at all

3

60

A

D

A

Worrying thoughts
go through my
mind:
A great deal of the
time

3

A lot of the time

2

From time to time,
but not too often

1

Only occasionally

0

I feel cheerful:
Not at all

3

Not often

2

Sometimes

1

Most of the time

0

I can sit at ease
and feel relaxed:
Definitely

0

Usually

1

Not Often

2

61
Not at all

D

A

D

3

I feel as if I am
slowed down:
Nearly all the time

3

Very often

2

Sometimes

1

Not at all

0

I get a sort of
frightened feeling
like 'butterflies' in
the stomach:
Not at all

0

Occasionally

1

Quite Often

2

Very Often

3

I have lost interest
in my appearance:
Definitely

3
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A

D

I don't take as much
care as I should

2

I may not take quite
as much care

1

I take just as much
care as ever

0

I feel restless as I
have to be on the
move:
Very much indeed

3

Quite a lot

2

Not very much

1

Not at all

0

I look forward with
enjoyment to
things:
As much as I ever
did

0

Rather less than I
used to

1

Definitely less than I
used to

2

63
Hardly at all

A

D

3

I get sudden
feelings of panic:
Very often indeed

3

Quite often

2

Not very often

1

Not at all

0

I can enjoy a good
book or radio or TV
program:
Often

0

Sometimes

1

Not often

2

Very seldom

3

Scoring (add the As =
Anxiety. Add the Ds
= Depression). The
norms below will give
you an idea of the
level of Anxiety and
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Depression.
0-7 = Normal
8-10 = Borderline
abnormal
11-21 = Abnormal

Reference:
Zigmond and Snaith (1983)

Appendix: Positive and Negative Affect Schedules (PANAS)
PANAS
This scale consists of a number of words that describe different feelings and emotions. Read
each item and then circle the appropriate answer next to that word. Indicate to what extent
you have felt this way during the past week.

1 = Very slightly or not at all

2 = A little

3 = Moderately

4 = Quite a bit 5 = Extremely

1. Interested

1

2

3

4

5

2. Distressed

1

2

3

4

5

3. Excited

1

2

3

4

5

4. Upset

1

2

3

4

5

65
5. Strong

1

2

3

4

5

6. Guilty

1

2

3

4

5

7. Scared

1

2

3

4

5

8. Hostile

1

2

3

4

5

9. Enthusiastic

1

2

3

4

5

10. Proud

1

2

3

4

5

11. Irritable

1

2

3

4

5

12. Alert

1

2

3

4

5

13. Ashamed

1

2

3

4

5

14. Inspired

1

2

3

4

5

15. Nervous

1

2

3

4

5

16. Determined

1

2

3

4

5

17. Attentive

1

2

3

4

5

18. Jittery

1

2

3

4

5

19. Active

1

2

3

4

5

20. Afraid

1

2

3

4

5

